AutoGenomics announced Nov. 2 the release of a series of pharmacogenetic ASRs, including CYP 450 2C9 / VKORC1, which can be used to assess warfarin sensitivity.
Other applications for the new ASRs include CYP 450 2D6, 2C19, NAT2, UGT1A1, MDR1 and 3A4/3A5 tests.
AutoGenomics CEO Fareed Kureshy touted the achievement as “the most comprehensive panel of ASRs made available by any company” and said the achievement positioned the company as a leader in personalized medicine.
The company has also submitted a 510(k) application for an automated multiplexing microarray platform that can provide amplified samples to test results without manual intervention by the operator.